Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.63 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 6/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetyl Tyrosine SCHEMBL7560086 | 1.00 | FOLH1 (0.63) | FOLH1NPY1RNPY2RNPY4RACE | |
| Levacetylleucine SCHEMBL8155903 | 0.91 | FOLH1 (0.64) | FOLH1NPY1RNPY2RNPY4RACE | |
| Levacetylleucine SCHEMBL8147909 | 0.91 | FOLH1 (0.60) | FOLH1NPY1RNPY2RNPY4RACE | |
| Afalanine SCHEMBL7553924 | 0.90 | LTA4H (0.62) | ACELTA4HMMECPA1ACE2 | |
| Afalanine SCHEMBL7553921 | 0.90 | LTA4H (0.62) | ACELTA4HMMECPA1ACE2 | |
| Acetyl Tyrosine SCHEMBL8938057 | 0.88 | MME (0.55) | FOLH1ACESLC7A5MMEOPRD1 | |
| Leucine Amide SCHEMBL6534879 | 0.86 | FOLH1 (0.58) | FOLH1NPY1RNPY2RNPY4RACE | |
| Acetyl Tyrosine SCHEMBL28266147 | 0.86 | FOLH1 (0.62) | FOLH1ACESLC7A5MMECPA1 | |
| Acetyl Tyrosine SCHEMBL17763856 | 0.86 | SLC7A5 (0.71) | FOLH1ACESLC7A5MMECPA1 | |
| Acetyl Tyrosine SCHEMBL17763855 | 0.86 | SLC7A5 (0.71) | FOLH1ACESLC7A5MMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020137124-A1 | Process for the continuous production of dipeptide crystals in a membrane and hydro-cyclone reactor using a peptidase | INSTITUTO SUPERIOR TECHNICO (PT) | 2002-09-26 | — | — | US | disclosed |
| WO-2001088175-A1 | PROCESS FOR THE CONTINUOUS PRODUCTION OF DIPEPTIDE CRYSTALS IN A MEMBRANE AND HYDRO-CYCLONE REACTOR USING A PEPTIDASE | INSTITUTO SUPERIOR TÉCNICO (PT) | 2001-11-22 | — | — | WO | disclosed |
| US-5508182-A | PRODUCING AMPHIPHILIC COMPOUNDS, 1-MONOGLYCERIDES, SUGAR ETERS ON SOLID SUPPORTS USING A HYDROLASE | SCHNEIDER MANFRED P (DE) | 1996-04-16 | — | — | US | disclosed |
| WO-1992014830-A1 | ENZYMATIC REVERSE HYDROLYSIS OF HYDROPHILIC SUBSTRATES - PREPARATION OF AMPHIPHILIC COMPOUNDS | SCHNEIDER MANFRED P (DE) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137124-A1 | Process for the continuous production of dipeptide crystals in a membrane and hydro-cyclone reactor using a peptidase | LCT, PEPD, CPN1 | FOLH1 44/4885NPY1R 294/4885NPY2R 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.